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Introduction
This third article for the 2014 Year in Review will report
publications from intensive care on severe infections
(including endocarditis and peritonitis), septic shock,
healthcare and ventilator associated pneumonia, highly
resistant bacteria, antimicrobial therapy (including an-
tibiotic stewardship, therapeutic drug monitoring and de-
escalation), invasive fungal infections, severe viral in-
fections, Ebola virus disease and paediatrics.
Sepsis
Circulatory dysfunction is frequently present in patients
admitted to the ICU. With the literature on diagnoses,
treatment and monitoring of shock updating frequently, it
is important to have up-to-date guidelines. An important
process to facilitate the establishment of national/local
guidelines is the production of a consensus statement of
scientific societies. Therefore the European Society of
Intensive Care Medicine formed a taskforce to review
literature and expert opinions on the diagnosis, treatment
and monitoring in circulatory shock. Their report was a
long expected update on the publication of the Interna-
tional Consensus Conference on hemodynamic
monitoring in shock in 2007 [1]. The Taskforce produced
44 statements using the GRADE system principles [2] and
included studies published up to October 1st 2014 [3].
Therefore this consensus statement published in Decem-
ber 2014 issue of Intensive Care Medicine represents a
very up-to-date view on current evidence. The Taskforce
recommends NOT using currently recommended preload
parameters as a sole target of fluid resuscitation or tar-
geting any ventricular filling pressure or volume. The
Taskforce recommends to fluid resuscitate patients using
more than one single hemodynamic variable and to use
dynamic instead of static variables to predict fluid re-
sponsiveness whenever possible. This is in sharp contrast
with the recently published Guidelines on the treatment of
sepsis and septic shock from the Surviving Sepsis Cam-
paign (SSC) [4]. In addition, guiding fluid resuscitation by
CVP might even prove to be harmful [5, 6]. Nevertheless
the use of the SSC guidelines has been reported to im-
prove survival from severe sepsis and septic shock [7].
Both the adherence to the resuscitation and the manage-
ment bundles of the guideline were associated with
improved survival. Participation of an individual site in
the SSC resulted in a significant drop in hospital mortality
every 3 months and increases in site compliance with the
resuscitation bundle significantly improved ICU and
hospital length of stay. In the context of the previous part
the question arises whether these important clinical ef-
fects of the SSC-guideline result from the adequacy of the
targets in the guideline or the effect of protocolized and
standardized care. Most likely it’s a combination of ef-
fects that warrants further optimization of the SSC-
guideline rather than discarding them [8].
The adequacy of (fluid) resuscitation in every kind of
circulatory failure depends on a good understanding of the
physiology of the circulation. Three publications have
contributed to this important aspect. Two publications
focused on the understanding of venous return [9] and
hypovolaemia [10]. These two topics are closely linked as
the therapy for hypovolaemia is increasing venous return.
The use of CVP in this context would be to assess whether
the heart can efficiently handle the increase in venous
return rather than using in increase in CVP as an indicator
of adequately increased venous return [9]. In the most
challenging circulatory failure (septic shock) where all
aspects of the three pillars of the circulation (the vascu-
lature, the volume and the heart) might be affected [9] the
understanding the pathophysiology of cardiac failure is
important as is likely to affect your treatment [11].
Important to realize is that the circulation volume is
not equal to the total blood volume. This mistake is fre-
quently made my junior doctors and nurses. In a
compensated state of hypovolemia, the total blood vol-
ume (the sum of stressed and unstressed volume) is
decreased while the stressed volume is maintained and
therefore cardiac output may be maintained as well. This
results from an increased activity of the sympathetic
nervous system that translates in clinical practice into
decreased peripheral perfusion. An important marker of
decreased peripheral perfusion is a prolonged capillary
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refill time [12]. Many studies have now shown that ab-
normal peripheral perfusion is an important warning sign
in critically ill patients. Whether this is abnormal skin
color [13], abnormal tissue hemoglobin saturation [14] or
increased capillary refill time [15, 16]. As abnormal pe-
ripheral tissue perfusion can be corrected by specific
therapy [17] the next logical step would be to incorporate
the use of peripheral perfusion parameters and specific
treatment into diagnostic and therapeutic protocols to
define efficacy of the use of these parameters [18].
Although many techniques are available to assess the
state of the circulation, echo (cardiography) has gained
importance over the last years. The Taskforce of the
ESICM recommends the use of echocardiography as the
preferred modality in patients where clinical examination
fails to determine the type of shock [3]. In addition,
echocardiography is noninvasive technique to sequen-
tially evaluate cardiac function in patients with
circulatory failure and thus preferred over the routine use
of a pulmonary artery catheter [3]. In mechanically ven-
tilated critically ill patients the use of lung ultrasound
significantly changes clinical decisions and therapeutic
management. In a study of 189 patients, therapy was
changed directly in 47 % of the patients [19]. In patients
the combination of lung ultrasound and echocardiography
has proven to be superior to using lung ultrasound only
[20]. Therefore thoracic echocardiography should be an
important competence of the current curriculum of a
trainee in intensive care.
Sepsis and endocrinopathy
The role of the hypothalamic–pituitary–adrenal axis
(HPA) in critically ill patients remains a subject of in-
terest as the discussion on supporting this axis by use of
hydrocortisone and vasopressin remains actual [21]. The
HPA hormones seem to be related to severity of disease in
early sepsis and progression to septic shock [22].
Although hydrocortisone has a vasopressor sparing effect,
it doesn’t seem to affect vasopressin levels nor mortality
[21]. The role of both thus needs more clarification before
recommendations for combined treatment can be made
[23]. Also the discussion on the use of vasopressin as a
hormone substitute or as a vasopressor needs clarification
as the use as a vasopressor is associated with serious
adverse events not related to vasopressin blood levels but
more to the presence of a specific genotype [24].
The interaction between immune system and infec-
tious organism in not fully understood. In a recent What’s
new article, Douglas et al. [25] emphasized the role of
innate response in sepsis. Indeed, Innate-like lymphocytes
are a recently described subset of the immune response
with known antibacterial properties. Human trial in
critically ill patients provides the first evidence of the
drop in MAIT cells during bacterial sepsis, which com-
pounds the already known immune defects. The persistent
depletion and potential for nosocomial infections is an
interesting finding and likely to provide fertile grounds for
future studies.
Infection and antimicrobial therapy
While it is now well recognized that early appropriate
antimicrobial therapy reduces infection-related morbidity
and mortality in the critically ill patients, the importance
of pharmacodynamic (PD) dosing to optimize drug ex-
posure continues to evolve. Since it is well recognized
that beta-lactams efficacy is driven by the time the drug
concentration exceeds the MIC (T [ MIC) of the target
pathogen, many of these strategies focused on altering
infusion times. In the clinical setting, beta-lactam opti-
mization strategies often include the use of a prolonged
infusion (i.e., same dose administered over 3–4 h) for
each dosing interval or as a continuous infusion where the
total daily dose is given at a constant rate over 24 h. Each
of these strategies has been reported to enhance the effi-
cacy when compared to conventional regimens as
reported by Bassetti et al. [26] in his editorial. In their
interesting and intriguing study, De Waele et al. [27],
using the DALI study (a prospective, multi-centre phar-
macokinetic point-prevalence study) shown that in 343
critically ill patients receiving 8 different b-lactam an-
tibiotics, antibiotic free drug concentrations remained
below the MIC during 50 and 100 % of the dosing in-
terval in 66 (19.2 %) and 142 (41.4 %) patients,
respectively. The use of intermittent infusion was sig-
nificantly associated with increased risk of non-attainment
for both targets; creatinine clearance was independently
associated with not reaching the 100 % free time above
MIC (fT [ MIC) target. The study demonstrated that
when simulating an empirical setting where a broad range
of pathogens at the susceptibility breakpoint is targeted,
that target attainment using conventional b-lactam an-
tibiotic dosing was generally inadequate. Although
several factors play a role, use of intermittent infusion
resulted in a three to four fold increase in the likelihood of
not reaching the desired PK/PD targets. In another study,
De Waele et al. [28] prospectively analyzed the effect of a
dose adaption strategy using daily therapeutic drug
monitoring (TDM) on the target attainment for
meropenem and piperacillin/tazobactam when pneumonia
was the primary infectious diagnosis. Forty-one patients
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were included in the study. Eighty-five percent of patients
in the TDM group needed dose adaptation, 5 required an
additional increase. At 72 h, target attainment rates for
100 % fT [ 4MIC and 100 % fT [ MIC were higher in
the TDM group: 58 vs. 16 % (p = 0.007) and 95 vs. 68 %
(p = 0.045), respectively. The study supports a strategy
of dose adaptation based on daily therapeutic drug
monitoring that lead to an increase in PK/PD target at-
tainment compared to conventional dosing in critically ill
patients with normal kidney function.
Aminoglycosides continue to be essential antibiotic in
ICU. When aminoglycosides are used in critically ill pa-
tients, it is crucial that their efficacy is maximized.
Aminoglycosides are concentration dependent antibiotics,
and the peak concentration over MIC is the relevant PK/
PD parameter. Studies have shown that aminoglycosides
have their maximal effect at a Cmax/MIC ratio of 8–10.
This means that TDM for efficacy may be helpful to guide
therapy. Based on these considerations, as well as on the
decreasing susceptibility of microorganisms, actual PK-
guided dosing based on individual plasma concentrations
is preferable in critically ill patients. Initial therapy
(before any MIC is known) should use higher doses
(amikacin 25–30 mg/kg, gentamycin 7–9 mg/kg and to-
bramycin 7–9 mg/kg) to compensate for the changes
described, and the Cmax of the previous dose should guide
subsequent doses as reported by Dimopoulos [29] in his
editorial. Under this context, recent studies shed more
light on the aminoglycoside PK/PD properties in ICU
patients. In a prospective study conducted by de Mont-
mollin et al. [30] in a general ICU, 33 % of patients that
receives a loading dose of amikacin of 25 mg/kg of total
body weight (TBW), still had an amikacin Cmax\60 mg/
L. Positive 24-h fluid balance was identified as a predic-
tive factor of Cmax \60 mg/L. Low BMI tended to be
associated with amikacin underdosing, when TBW was
used, suggesting the need for higher doses in patients with
a positive 24-h fluid balance. Whether these regimens are
associated with improved outcomes is unknown, therefore
other prospective randomized controlled studies are
warranted to assess the effects of higher loading doses of
amikacin on Cmax, infection control and survival, and its
impact on renal and hearing functions.
Other compound such as tigecyclin has been exten-
sively studied because of potential activities on
extensively drug-resistant bacterias. In 2010 and 2013, the
US Food and Drug Administration (FDA) reported an
increased risk of mortality associated with tigecycline use
in comparison with other drugs in the treatment of serious
infections. The analysis used a pooled group of random-
ized clinical trials including hospital-acquired pneumonia
(HAP) and ventilator-associated pneumonia (VAP),
complicated skin and soft tissue infections (cSSTI),
complicated intra-abdominal infections (cIAI), and
diabetic foot infections. On the basis of the pooled data
analysis, the FDA recommended that alternatives to
tigecycline should be considered in patients with severe
infections. In their interesting article Montravers et al.
[31] conclude that tigecyclin success rates in patients in
ICU with severe infections appear comparable to those
reported with other antibiotics; the overall success rate
was 60 % at the end of treatment, and 53 % 7 days later.
Furthermore, they report a survival rate of 85 % at day
28. Historically, clinical trials concerning management of
critically ill and particularly ICU-admitted patients with
tigecyclin are limited. Despite the obscure vision pro-
vided by an impressive number of meta-analyses,
tigecyclin is expected to be used more often in approved
indications and in off-label combination regimens for the
treatment of MDR gram-negative infections in routine
clinical practice. This is greatly supported by the Mon-
travers study mentioned above. The increased medical
need represented by the growing impact of multiresistant
infections and the current lack of alternative or new an-
tibiotics suggests that tigecycline benefit–risk continues to
be positive.
Antimicrobial de-escalation
Another way to save antimicrobials is to deescalate as
often as possible. Many important papers have been
published in the journal on this field.
Antimicrobial de-escalation is a clinical approach to
empirical antibiotic treatment of serious infections that
attempts to balance the need for appropriate initial ther-
apy with the need to limit unnecessary antimicrobial
exposure in order to curtail the emergence of resistance.
Although the concept of antimicrobial de-escalation
seems to make intuitive sense, clinicians should ask
themselves what the realistic expectations of such a
strategy are. Intensivists should expect that a de-escala-
tion approach to antimicrobial therapy in critically ill
patients will optimize patient’s outcomes as said by Dr
Kollef [32] in his editorial. In his interesting and complete
study, Garnacho-Montero et al. [33] evaluated 628 pa-
tients with severe sepsis or septic shock at ICU admission
who were treated empirically with broad-spectrum an-
tibiotics. Antibiotic therapy was guided by written
protocols advocating for de-escalation therapy once the
microbiological results became available (day of culture
results), although this decision was ultimately the re-
sponsibility of the physician in charge of the patient. By
multivariate analysis, factors independently associated
with in-hospital mortality were septic shock, SOFA score
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on the day of culture results, and inappropriate empirical
antimicrobial therapy, whereas de-escalation of antimi-
crobial therapy was found to be a protective factor for
hospital survival. Additionally, among patients receiving
appropriate therapy the only factor independently asso-
ciated with mortality was SOFA score on the day of
culture results, whereas de-escalation therapy was again
found to be a protective factor.
In the setting of neutropenic patient with severe sepsis
or septic shock, use of broad-spectrum antibiotics is rec-
ommended. To date, the first study on the safety of de-
escalation in neutropenic patients has been published in
this journal by Mokart et al. [34]. De-escalation of an-
timicrobial therapy consisted either to delete one of the
empirical antibiotic of a combined treatment, or, when-
ever possible, to use a betalactam antibiotic with a
narrower spectrum of activity. Cumulative incidence of
de-escalation of the empirical antimicrobial treatment
among the 101 patients of the cohort, was 44 %, (95 %
confidence interval, CI 38–53 %), including 30 (68 %)
patients with ongoing neutropenia, while a micro-
biological documentation was available in 63 (63 %)
patients. De-escalation did not significantly modify the
hazard of death within the first 30-day [HR = 0.51 (95 %
CI 0.20–1.33)], nor within the 1 year after ICU-discharge
[HR = 1.06 (95 % CI 0.54–2.08)]. The results of the
study are encouraging and impressive: for the first time
the authors has shown that, in ICU, de-escalation is fre-
quently performed in neutropenic cancer patients with
severe sepsis and this approach appears not to affect the
outcomes.
Surprising and apparently not expected results for de-
escalation therapy were shown by Leone et al. [35] in
their multicenter, non-blinded, randomized noninferiority
trial included patients with severe sepsis that were ran-
domly assigned to de-escalation or continuation of
empirical antimicrobial treatment. The results shown the
median duration of ICU stay was 9 [interquartile range
(IQR) 5–22] days in the de-escalation group and 8 (IQR
4–15) days in the continuation group, respectively
(p = 0.71). The mean difference was 3.4 (95 % CI -1.7
to 8.5). A superinfection occurred in 16 (27 %) patients in
the de-escalation group and six (11 %) patients in the
continuation group (p = 0.03). The numbers of antibiotic
days were 9 (28–30, 36–41) and 7.5 (27–30, 36–39) in the
de-escalation group and continuation group, respectively
(p = 0.03). Mortality was similar in both groups. The
current study casts significant doubt whether the reduction
of the spectrum of the antibiotic can be considered safe as
a routine measure. The authors demonstrated that de-
escalation, defined as narrowing the spectrum of the an-
tibiotic, was inferior to continuation of the initial
antibiotic therapy with length of stay as the primary
outcome parameter. Furthermore, antibiotic use was
higher in the de-escalation group presumably driven by
the number of superinfections in the de-escalation group.
A key element in the study of the potential role of de-
escalation is a uniform definition of de-escalation. De-
escalation—defined as narrowing the spectrum of an an-
tibiotic treatment—should be cautiously applied, based on
each particular patient’s clinical status and considering
the ICU environment as a whole.
Healthcare-associated pneumonia
Valle´s et al. [42] prospectively compared the epidemi-
ology, antibiotic therapy and clinical outcomes between
449 patients with community acquired pneumonia (CAP),
133 health care acquired pneumonia (HCAP) and 144
immunocompromised patients (ICP) with pneumonia
admitted in 34 Spanish ICUs over a 1 year period. They
found that HCAP patients had more comorbidities and
had a worse clinical status as compared to the two other
subgroups and that both HCAP and ICP more often
needed mechanical ventilation and more often underwent
tracheostomy. The incidence of gram-negative pathogens,
MRSA and Pseudomonas aeruginosa was low overall,
but higher in HCAP and ICP. Inappropriate empirical
antibiotic therapy was 6.5 % in CAP, 14.4 % in HCAP
and 38.6 % in ICP while mortality was the highest in ICP
(38.6 %) and did not differ between CAP (18.4 %) and
HCAP (21.2 %). The authors concluded that empirical
antibiotic regimens recommended for CAP would be
appropriate for 90 % of the patients with HCAP and that
consequently systematically covering multidrug-resistant
pathogens in HCAP is not necessary.
Ventilatory-acquired pneumonia
Diagnosis of ventilator-associated pneumonia (VAP) is a
problem that is not yet fully solved. In fact, there have been
no major advances since the last meta-analysis published
by the Cochrane Collaboration [43]. Real major advances
will come from rapid PCR point-of-care techniques, but
these results are not yet available. In 2014, Bos et al. [44]
published an article in the What’s New in Intensive Care
section on potential innovations that could improve early
recognition of VAP. Those authors suggested that new
techniques are promising in detecting airway colonization
and pulmonary infection at the early phase. The first
technique would use colorimetric assays inside the endo-
tracheal tubes to detect the type of bacteria and the pattern
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of resistance. The second technique is based on the de-
tection of volatile compounds (hydrocarbons, alcohols,
aldehydes, ketones and, sulfide-containing molecules) re-
leased by bacteria that cause VAP. These techniques are
still in a very early clinical phase and need to be validated.
Postoperative nosocomial pneumonia is a threatening
complication of major surgery (cardiovascular, thoracic
and abdominal), with very high morbidity and mortality.
All improvements that can help prevent postoperative
pneumonia are welcome. Preoperative oral care is a non-
standard prophylactic measure. Bergan et al. [45] per-
formed a prospective study implementing several oral-
hygiene measures, including a dentist visit, brushing teeth
and tongue and, oral rinse with chlorhexidine (0.12 %)
twice a day until surgery. With these measures, they were
able to reduce pneumonia from an incidence rate of 32
cases to 1000 ventilator days in the 6 months period be-
fore the study to 10 cases per 1000 days of mechanical
ventilation during the 6 months following the study. Oral
chlorhexidine rinsing in the preoperative period (OR, 17)
and on the day of surgery significantly were significantly
protective for post-operative pneumonia. Oral chlorhex-
idine rinses and dental hygiene are cheap, easy and
effective measures for preventing pneumonia after cardiac
surgery.
Colonization with resistant bacteria
Colonization is a better indicator for bacterial dynamics
than infection, since colonization only leads to infection
in a small group but contributes significantly to the
epidemiology of these bacteria. Knowledge about the
time until clearance of resistant bacteria is of great
importance for understanding nosocomial dynamics and
for predicting effects of interventions. In his study
Haverkate et al. [46] studied all patients screened on
admission and twice weekly for resistant bacteria in 13
ICUs in 8 European countries (MOSAR-ICU trial,
2008–2011). 125 unique patients had 141 episodes of
colonization and at least one readmission. Thirty-two
patients were colonized with two or more resistant
bacteria. Median times until clearance were 4.8 months
for all resistant strains, 1.4 months for highly resistant
enterobacteriaceae, less than 1 month for MRSA, and
1.5 months for vancomycin resistant enterococci. For
all antimicrobial-resistant bacterial species, 50 % of the
patients had lost colonization when readmitted two or
more months after the previous ICU admission.
Although this study was performed on a selection of
hospital patients (i.e., patients admitted to ICUs), the
results are of critical importance since these patients are
especially prone to colonization and (subsequent)
infection.
Bacteremia and MRSA
Bacteremia is one of the major causes of nosocomial in-
fection in the intensive care unit (ICU), ICU-acquired
bloodstream infection (ICU-BSI) is associated with in-
creased morbidity and length of stay, resulting in excess
costs and high mortality of critically ill patients. Although
there are variations due to heterogeneous information
sources and variety of local clinical practices, coagulase-
negative staphylococci, Staphylococcus aureus, and En-
terobacteriaceae species are the pathogens most
frequently responsible for nosocomial bacteremia. Energy
deficit in ICU patients is mainly caused by reduced intake
due to under-prescribed calories and frequent feeding
interruptions. Cumulated energy deficit build-up during
the first days of ICU stay appears an independent factor
contributing to nosocomial infections. In their interesting
study, Ekpe et al. [47] investigated the impact of energy
deficit on the microbiological results of the blood cultures
of prolonged acute mechanically ventilated patients who
experienced a first ICU-BSI episode. Daily energy bal-
ance was compared according to the microbiological
results of the blood cultures of 92 consecutive prolonged
([96 h) acute mechanically ventilated patients who de-
veloped a first episode of ICU-BSI. Among the 92 ICU-
BSI, 9 were due to methicillin-resistant Staphylococcus
aureus (MRSA). The cumulated energy deficit of patients
with MRSA ICU-BSI was greater than those with ICUBSI
caused by other pathogens. ICU admission, risk factors
for nosocomial infections, nutritional status, and condi-
tions potentially limiting feeding did not differ
significantly between the two groups. Patients with
MRSA ICU-BSI had lower delivered energy and similar
energy expenditure, causing higher energy deficits. More
severe energy deficit and higher rate of MRSA blood
cultures (p = 0.01 comparing quartiles) were observed.
The conclusions of the study were that early in-ICU en-
ergy deficit was associated with MRSA ICU-BSI in
prolonged acute mechanically ventilated patients. Results
suggest that limiting the early energy deficit could be a
way to optimize MRSA ICU-BSI prevention.
Bacteremia is an important cause of mortality, pro-
longed stay and excess healthcare costs even in paediatric
intensive care units (PICU). An estimated 70 % of BSIs
occurring in PICU are thought to be related to the use of
central venous catheters (CVCs). Adherence to full sterile
procedures may be compromised when CVCs are inserted
as part of emergency resuscitation and stabilisation, par-
ticularly outside the intensive care unit. Half of
emergency admissions to PICU in the UK occur after
stabilisation at other hospitals. In their study Harron et al.
[48] made in UK determined whether bloodstream in-
fection (BSI) occurred more frequently in children
admitted to PICU after inter-hospital transfer compared to
within hospital admissions. Multivariable regression
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showed no significant difference in rates of PICU-ac-
quired BSI by source of admission (incidence-rate ratio
for inter-hospital transfer versus within-hospital admis-
sion = 0.97, 95 % CI 0.87–1.07) after adjusting for other
risk-factors. Rates of inter-hospital transfers decreased
more rapidly between 2003 and 2012: 17.0 % (95 % CI
14.9–19.0 % per year) compared with 12.4 % (95 % CI
9.9–14.9 % per year) for within hospital admissions. The
median time to first PICU-acquired BSI did not differ
significantly between inter-hospital transfers (7 days, IQR
4–13) and within-hospital admissions (8 days, IQR 4–15).
The authors concluded that inter-hospital transfer was no
longer a significant risk factor form PICU-acquired BSI.
Given the large proportion of infection occurring in the
second week of admission, initiatives to further reduce
PICU-acquired BSI should focus on maintaining sterile
procedures after admission.
Peritonitis
Faecal peritonitis (FP) is a common cause of secondary
peritonitis caused by spillage of faecal material from the
large bowel into the peritoneum. The Genetics of Sepsis
and Septic Shock in Europe (GenOSept) project is in-
vestigating the influence of genetic variation on the host
response and outcomes in a large cohort of patients with
sepsis admitted to ICUs across Europe. Tridente et al. [49]
reported in their study data for 977 FP patients admitted
to 102 centers across 16 countries. The most common
causes of FP were perforated diverticular disease
(32.1 %) and surgical anastomotic breakdown (31.1 %).
The ICU mortality rate at 28 days was 19.1 %, increasing
to 31.6 % at 6 months. The cause of FP, pre-existing co-
morbidities and time from estimated onset of symptoms to
surgery did not impact on survival. The strongest inde-
pendent risk factors associated with an increased rate of
death at 6 months, included age, higher APACHE II
score, acute renal and cardiovascular dysfunction within
one week of admission to ICU, hypothermia, lower hae-
matocrit and bradycardia on day 1 of ICU stay.
Infective endocarditis
Although recent literature is plenty of studies concerning
all aspects of infective endocarditis (IE), very few focus
on severe IE requiring admission to the ICU. In their
‘‘My paper 10 years later’’ Wolff et al. [50] affirmed that
since the publication of the paper in 2004 a lot of in-
formation has been accumulated on management of IE.
While 3 sets of blood cultures allow the identification of
about 90 % of cases, culture negative IE still remains a
diagnostic challenge. Blood-polymerase chain reaction in
valve tissue may yield a microbiologic diagnosis. New
imaging techniques such as PET-CT scans have shown
additive value in patient with intra-cardiac device or
valvular prosthesis. Systematic cerebral magnetic reso-
nance imaging can lead to modification of therapeutic
plans. The decision to operate and the timing of cardiac
surgery should take into account the presence of con-
gestive heart failure, neurological complications, renal
failure, and multiorgan dysfunction syndrome. The
strongest independent predictor of post-operative mor-
tality was the pre-operative multiorgan failure score.
Neurological failure also represented a major determi-
nant of mortality, regardless of the mechanism of
neurological complication.
Fungal infections and colonization
Fungal infections and in particular Candida species are
responsible for between 9–12 % of all bloodstream in-
fections and are the fourth most common cause of
nosocomial bloodstream infections in most US population
surveys and the sixth or seventh most common cause in
European surveys. Candida bloodstream infections occur
at highest rates in the ICU population, with this setting
accounting for 33–55 % of all candidemias. In their
complete and useful review Leon et al. [36] described that
a high proportion of ICU patients become colonized with
Candida species, but only 5–30 % develop invasive
candidiasis. Invasive candidiasis and candidaemia are
difficult to predict and early diagnosis remains a major
challenge. In addition, microbiological documentation
occurs often late in the course of infection. Delays in
initiating appropriate treatment have been associated with
increased mortality. In an attempt to decrease Candida-
related mortality, an increasing number of critically ill
patients without documented candida infections receive
empirical systemic antifungal therapy, leading to concern
for antifungal overuse. Scores/predictive rules permit the
stratification and selection of high risk patients who may
benefit from early antifungal therapy. However, they have
a far better negative predictive value than positive pre-
dictive value. New biomarkers [mannan, antimannan,
(1,3)-b-D-glucan and polymerase chain reaction] are be-
ing increasingly used to enable earlier diagnosis and,
ideally, to provide prognostic information and/or
therapeutic monitoring. Although reasonably sensitive
and specific, these techniques remain largely investiga-
tional, and their clinical usefulness has yet to be
established.
In their elegant study, Lortholary et al. [37] reported
the active hospital-based surveillance program of incident
episodes of candidemia in twenty-four tertiary care
581
hospitals in Paris area. Among 2507 adult cases included,
2571 Candida isolates were collected and species were C.
albicans (56 %), C. glabrata (18.6 %), C. parapsilosis
(11.5 %), C. tropicalis (9.3 %), C. krusei (2.9 %) and C.
kefyr (1.8 %). Candidemia occurred in ICU in 1206 pa-
tients (48.1 %). When comparing ICU vs. non-ICU
patients, the former had significantly more frequent sur-
gery during the past 30 days, were more often pre-
exposed to fluconazole and treated with echinocandin,
and were less frequently infected with C. parapsilosis. A
significant increased incidence in the overall population
and ICU was found. Echinocandins initial therapy in-
creased over time in ICU (4.6 % first year of study, to
48.5 % last year of study, p \ 0.0001). ICU patients had a
higher day 30 death rate than non-ICU patients [odds ratio
(OR) 2.12, 95 % CI 1.66–2.72, p \ 0.0001]. The day 30
and early (\day 8) death rates increased over time in ICU
(from 41.5 % the first to 56.9 % the last year of study
(p = 0.001) and 28.7–38.8 % (p = 0.0292), respective-
ly). The authors concluded that the availability of new
antifungals and the publication of numerous guidelines
did not prevent an increase of candidaemia and death in
ICU patients in Paris area. Apparently in contrast with the
Paris study, Colombo et al. [38] retrospectively analyzed
1392 episodes of candidaemia in adult patients (647 in
ICU) from 22 Brazilian hospitals. Comparing the char-
acteristics of candidaemia in ICU patients in 2 periods
(2003–2007, period 1 and 2008–2012, period 2), and
assessed predictors of 30-day mortality. They reported
that 30-day mortality rate decreased from 76.4 % in pe-
riod 1–60.8 % in period 2 (p \ 0.001). Predictors of
30-day mortality by multivariate analysis were older age,
period 1, receipt of corticosteroids and higher APACHE II
score, while treatment with an echinocandin were asso-
ciated with a higher probability of survival. The authors
concluded that the incorporation of echinocandins as
primary therapy of candidemia seems to be associated
with better outcome. As in bacterial infections however,
adequate treatment remains of paramount importance in
treating infections in critically ill patients. Also in patients
with candida blood stream infections, inadequate source
control and antifungal treatment have been associated
with increased mortality [51]. Another important phe-
nomenon in the management of Candida infections is
represented by the emergence of resistance in Candida
spp. Antifungal drug resistance was considered less
problematic in Candida spp. than in other pathogens, but
recent increases in resistance to both echinocandins and
azoles have led to clinical failures. In their extensive re-
view Maubon et al. [39] reported that acquired
fluconazole resistance is frequent in C. glabrata (from 4
to 16 %), which increasingly displays cross-resistance to
voriconazole. So far, multi-drug resistant phenotype
against azole and echinocandins, has only been described
for C. glabrata and is a matter of serious concern.
Fluconazole resistance remains uncommon in C. albicans
(\5 %), but is more prevalent in C. parapsilosis (4–10 %)
and C. tropicalis (4–9 %), however recent data shows that
may reflect geographical differences. Acquired resistance
to echinocandins is increasingly reported for most of the
clinically important Candida spp. It remains uncommon
in C. albicans (\1 %), C. tropicalis (\5 %) and C. krusei
(\7 %), but is now becoming frequent in C. glabrata
(8–15 %).
Candida spp. colonization of the airway is frequently
reported in mechanically ventilated critically ill patients,
and its clinical significance is difficult to evaluate. Can-
dida has a low affinity for alveolar pneumocytes and
histologically documented pneumonia has been rarely
reported. Hematogenous dissemination in the context of
candidemia may be responsible for multiple pulmonary
abscesses and should be viewed as a distinct entity. Hence
the existence of true candidal pneumonia is doubtful and
recovery of Candida spp. from the respiratory tract should
generally be considered as colonization and does not
justify antifungal therapy. In their double-blind, placebo-
controlled, multicenter pilot randomized trial, Martin
et al. [40] tried to demonstrate a benefit of antifungal
therapy in critically ill patients with positive airway se-
cretion specimens for Candida spp. They recruited 60
patients into the randomized trial: 29 patients specifically
treated with antifungals. Markers of inflammation and all
clinical outcomes were comparable between placebo and
antifungal treatment group at baseline and over time. At
baseline, plasma TNF-alpha levels were higher in the
patients colonized with Candida compared to the obser-
vational group (mean ± SD) (21.8 ± 23.1 vs.
12.4 ± 9.3 pg/ml p = 0.02) and that these patients had
lower innate immune function as evidenced by reduced
whole blood ex vivo LPS-induced TNF-alpha production
capacity (854.8 ± 855.2 vs. 1559.4 ± 1290.6 pg/ml
p = 0.01). This study does not provide evidence to sup-
port a larger trial examining the efficacy of empiric
antifungal treatment in patients with Candida in the en-
dotracheal secretions. Similar negative impact in duration
of mechanical ventilation has been obtained with inhaled
amphotericin-B patients with airway colonization with
Candida sp. Ampho-B inhalation therapy was not asso-
ciated with increased decolonization and might even
prolong duration of mechanical ventilation possibly due
to the toxicity of the drug on the lungs [52].
In addition, in a small randomized study on the effi-
cacy of empiric treatment of suspected ventilator
associated pneumonia in patients with candida coloniza-
tion of the respiratory tract did not prove to be effective
[40]. In this study persistent inflammation and immuno-
suppression were associated with Candida colonization of
the lung. What to do with respiratory tract colonization in
critically ill patients therefore remains an important
problem [53].
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For the prevention of fungal infections, oral prophy-
laxis with nystatin has been recently evaluated and
shown to result in a reduction of Candida colonization
[41].
The development of the Candida colonization index
(CI) has been viewed as a major conceptual advance in
the characterization of supporting the progression from
colonization to infection in surgical patients [54]. In their
‘‘My paper twenty year later’’ Eggimann et al. [55] af-
firmed that since the publication of the paper in 1994,
many centers have used the CI or a methodology derived
from its original description to assess the dynamics of
Candida colonization in different sub-groups of critically
ill patients at risk of invasive candidiasis. Unfortunately,
these data have not been validated in large multicenter
trials. Several studies have indirectly suggested the va-
lidity and potential usefulness of the CI, but almost
exclusively in surgical patients. Among the pitfalls, it
should be emphasized that it is work-intensive with a
limited bedside practicability. Furthermore, only limited
data are available for nonsurgical patients, and its cost
effectiveness and usefulness for the management of
critically ill patients remain to be proven in large
prospective clinical trials.
Koulenti et al. [56] analyzed data on epidemiology,
clinical aspects and diagnostic novelties in invasive pul-
monary aspergillosis (IPA) in ICU patients. They
concluded that the identification of high-risk profiles for
IPA of ICU patients without apparent immunosuppression
might help in achieving earlier IPA diagnosis as it would
lead to a higher level of suspicion and a lower threshold to
perform thorough diagnostic work-out for patients at
high-risk. Epidemiological research with the aim to
identify the high-risk patient for IPA is going on
(http://www.aspicu2.org).
In recent years, antineoplastic treatment regimens in
hematological patients have intensified. This has led to a
significant increase in ICU admissions due to severe in-
fectious complications. Among these patients, pulmonary
infiltrates with a fungal etiology are among the most
common findings associated with febrile episodes. The
increasing availability of high resolution and multislice
CT has rendered the conventional chest radiograph more
or less obsolete for diagnosing lung infiltrates in febrile
neutropenic patients [57].
Viral pneumonia
In recent years, viral community-acquired pneumonia
(CAP) has been reported as a frequent microbial etiology
in severe CAP. This is due in part to the new diagnostic
techniques that allow to detect old and new viruses.
Middle East respiratory syndrome (MERS) is one of these
new viral diseases, which is caused by an RNA beta-
coronoravirus. Leung and Gomersall [58] described in
Intensive Care Medicine the epidemiology, pathogenesis,
clinical features, diagnosis, treatment, and implications
for intensive care management. The clinical features of
this disease are indistinguishable from other viral dis-
eases, including viral pneumonitis. Diagnosis is made by
means of epidemiological background (Middle-East
travel) plus the examination of blood, urine, stool, con-
junctival swabs and cerebrospinal fluid samples, in which
the virus can be found using real-time reverse-transcrip-
tion PCR. Most patients admitted to the ICU require
mechanical ventilation. Shock and renal failure are also
frequent. Unfortunately, there is no specific antiviral
treatment.
Ebola infection
Ebola virus is one of the most virulent human pathogens.
Since 1976, Ebola virus disease (EVD) has caused more
than 20 outbreaks in Africa, with case fatality rates of
30–90 %, in the absence of any approved treatment or
vaccination. It is transmitted by direct contact through
broken skin or mucous membranes with blood, urine,
saliva, feces, vomit, and other body fluids of symptomatic
infected patients or convalescent persons, or through
contaminated needle sticks. The 2014 EVD outbreak in
West Africa is a public health emergency of international
concern. Tattevin et al. [59] affirmed that every physician
active in emergency departments or ICU worldwide may
turn out to be involved in the care of patients suspected of
EVD. Their take-home messages from this paper were (1)
suspect EVD in any patient who presents with fever
within three weeks after a stay in Guinea, Sierra Leone,
Liberia, or Nigeria; (2) while implementing infection
control procedures to prevent any secondary cases (in
case EVD is confirmed), ensure that all plausible differ-
ential diagnoses are appropriately considered and
managed.
Even Parkes-Ratanshi et al. [60] in their article ur-
gently recommend that health facilities consult national
guidelines on EVD and develop local action plans. During
this epidemic this internet and social media such as
Twitter are being effectively used to disseminate infor-
mation by the WHO, governments and the medical press.
As the WHO are predicting that that the end of the epi-
demic is far away and it may infect up to 100,000 people
before it is controlled; it is essential that the global
medical community remains informed and vigilant. The
critical care teams working with patients who have been
evacuated to resource rich settings during the current
epidemic must share their best practices as soon as
possible.
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Regarding the organ dysfunction, Beeching et al.
[61] in their article explained that the pathogenesis of
EVD shows both similarities with and differences from
other causes of viral haemorrhagic fever or bacterial
sepsis. Systematic prospective observational studies are
essential to clarify the pathogenesis and pathophysiology
of disease in humans and to inform the development of
evidence based clinical scoring systems and manage-
ment algorithms, as well as the evaluation of novel
therapeutic agents. Improving access to basic supportive
care is essential. The role and possible benefit of more
aggressive critical care interventions continue to be
debated.
Paediatrics
Deep trouble: unwanted effects of sedation
and support
We have had a year of notable submissions including
novel reviews of large datasets, randomized controlled
trials, and state-of-the-art ‘‘What’s new’’ articles. How-
ever, arguably the most compelling piece of paediatric
intensive care literature from 2014 in ICM was the simple
but profound recollection of a month spent on a paediatric
intensive care unit: ‘Coma alarm dreams’ [62]. Written by
a remarkable young man describing his recovery from a
gunshot wound to the head, this 500-word piece provides
an uncomfortable insight into our patient’s experiences.
We may hardly notice monitor alarms; they form the
soundtrack of our working lives. But for our patients the
experience may be the complete opposite: dreams,
nightmares and hallucinations.
Dr Emeriaud and colleagues [63] from Montreal,
highlighted another problem during paediatric critical
illness that is easily overlooked. They performed re-
peated estimations of maximal inspiratory diaphragmatic
electrical activity (EAdimax) in 55 ventilated children.
This first systematic description of the natural history of
this parameter provides in number of insights; there
were frequent periods of little or no detectable di-
aphragmatic activity during mechanical ventilation;
those values that were seen during during full ventila-
tion were much lower than pre-extubation or
spontaneous breathing; and patients intubated mainly
because of a lung pathology exhibited higher EAdi
(p \ 0.01) than did patients supported for other reasons.
The authors add to the emerging view that we may be
oversedating and oversupporting many of our patients.
The possibility of using EAdi as a proxy endpoint for
clinical trials or as a biomarker for guiding mechanical
ventilation is intriguing.
Ventilation/ARDS
‘‘How to manage ventilation in pediatric acute respiratory
distress syndrome’’ by Kneyber, Jouvert and Rimens-
burger [64] returned to this theme of the limitations of our
current practice and the need to recognize the potential
harm we might be causing. They present a candid view of
the many gaps in our knowledge: is our (new) Berlin
definition sufficient for selection of patients for random-
ized trials? Is it appropriate to infer guidance from adult
studies? Does *6 mls/kg tidal volume really represent
our best guess safe and effective ventilation during both
acute and recovery phase of lung injury? Can we generate
clinically meaningful guidance from the bedside tools
such as transpulmonary pressure (TPP) measurements and
electrical impedance tomography (EIT)? Perhaps most
pressingly, many paediatric intensivists treasure the use of
high frequency oscillation in paediatric ARDS on very
limited evidence. Surely we need clinical trial data in the
face of the results from the Oscillate and Oscar trials. We
are again challenged to provide data to systematise our
sedation and weaning policies.
ECMO
Drs MacLaren, Brown and Thiagarajan [65] gave us a
view of ‘‘What’s new in pediatric ECMO’’ from four
continents. Overall survival after ECMO is improving and
therefore other indications are starting to be considered
(bridge to lung transplantation anyone?). They high-
lighted specific area of concerns including the need for
more information about advantages of specific pumps or
anticoagulant regimens. But above all there is a clear need
for long-term follow up. Recent reports of very high rates
of late death for cardiac ECMO make this point starkly:
only 10 % of hypoplastic left heart syndrome cases who
received ECMO were alive 5 years later. The impact on
the family with high rates of post-traumatic stress, the
importance of neurological complications, and the value
of neurodevelopment follow-up, as highlighted in the
journal in 2013, were noted [66–68].
Non-invasive ventilation
At the other end of the spectrum of severity of respiratory
failure, we published an important study from Kremlin-
Bicetre Hospital in Paris, documenting the associations of
a change in practice from predominantly invasive venti-
lation to predominantly nasopharyngeal CPAP support in
584
infants with bronchiolitis [69]. The authors readily ac-
knowledge that they cannot account for potential
confounders that might arise from other changes in
practice or case mix. That said, the numbers of cases
observed (n = 525) and the size of the effect: 81 % in-
vasive ventilation falling to 12 % over 10 years with
associated significant reductions in length of stay and
costs mean that we should not ignore these data.
The increasing options and environments in which
non-invasive ventilation may be useful was highlighted
by Dr Schlapbach and colleagues [70] from Brisbane
Australia. High-Flow Nasal Cannula was increasingly
used in predominantly aeromedical transports over a
median distance of 205 km. The availability of HFNC
was associated with a reduced need for intubation when
adjusted for PIM2 score, age, and the presence respiratory
disease. Changes in the case mix received in Brisbane do
limit the interpretation of these data but they form part of
a steady trend towards increasing use of non-invasive
support in our speciality. This was reviewed by Argent
and Biban [71] who asked: ‘‘What’s new on NIV in the
PICU: does everyone in respiratory failure require endo-
tracheal intubation’’? In this piece they highlighted the
very few published randomised studies (5) and prospec-
tive cohort studies (10) which represent the best data on
NIV in paediatric critical illness currently available. One
of the problems around generating evidence is the variety
of techniques, triggering mechanisms, patient interfaces
as well as options for patient selection and timing. These
combine to make good research in this area difficult.
However this is no excuse for not attempting it. Argent
and Biban put it clearly: Non-invasive techniques have
potential to ‘‘substantially improve the safety of ventilator
support for children, and improve access to ventilatory
support for both acute and chronic conditions. Given that
respiratory problems are among the most important cause
of childhood deaths across the world, it behoves us to
explore the potential and collect the data.’’
Paediatric airway
Research on the paediatric airway was a strong theme in
this year’s ICM. Dr Wakeham and colleagues [72] used
the Virtual Paediatric Intensive Care database to docu-
ment the very wide variability in practice around
tracheostomy use on 82 North American paediatric in-
tensive care units. Only 6.6 % of 13,323 admissions
underwent tracheostomy at a median length of stay of
14 days. Interquartile range was 7.4–25.7 days.
Tracheostomy rate amongst the larger contributors to the
study varied from 0 to 13.4 %. The authors right suggest
that these differences are unlikely to be attributable to
case mix differences alone. This sets paediatric
intensivists a serious challenge to remove unhelpful
variability on practice.
Dr Baranwal and colleagues [73] made a valuable
contribution to another unknown in paediatric airway
management. They asked if 24-h dexamethasone pre-
treatment was superior to 6-h pretreatment for prevention
of postextubation airway obstruction in children? They
recruited 124 children between the ages of 3 months and
12 years in an elegant randomized double-blind trial. The
two groups were similar at baseline. The longer (24 h)
pre-treatment significantly reduced both the incidence
(24 h pre-treatment 65 %, 43/66 vs. 6 h 83 %, 48/58;
p = 0.02, relative risk 0.79, 95 % CI 0.63–0.97) [74] and
duration of post-extubation airway obstruction as assessed
by a modified croup score. The longer pre-treatment
halved the re-intubation rate (0.53, 95 % CI 0.19–1.49):
but the study was not powered to detect a difference in
these relatively rare events (only 14 re-intubations took
place in the study). The implications of these data are not
clear since pre-treating for 24 h might mean delaying
extubation in some scenarios.
Outcome prediction
Prince et al. [75] from London examined the association
of ‘weight-for-age’ and case mix adjusted outcomes in
14,307 critically ill children. In addition to the size of this
dataset, a strength was the comparison to a healthy ref-
erence population in the United Kingdom. Not
surprisingly, critically ill children have lower weight-for-
age than do their healthly peers. This study confirmed the
findings amongst adults and in smaller paediatric studies
that children with weight-for-age above the population
mean have significantly better case-mix adjusted survival.
The similar ‘obesity paradox’ has been observed in adults
with sepsis. Indeed the association of weight-for-age and
standardised mortality ratio follows a U-shaped distribu-
tion (as do many things in intensive care). The
accompanying editorial from Nadel and Argent points out
how much more information we need to understand the
nutritional needs of our patient [76].
Zinter et al. [77] described outcomes for 10,365 pae-
diatric cancer emergency admissions out of 246,346
admissions to the US virtual PICU systems database. A
diagnosis of leukaemia of lymphoma ‘outside of first in-
duction,’ still carries a ‘high-risk’ tariff in the Paediatric
Index of Mortality scoring system at ICU admission [78].
But things may be changing. Overall survival for paedi-
atric cancer continues to improve with 83 % 5 year
survival but 38 % of paediatric cancer patients make at
least one visit to the ICU. This large series observed only
a 6.8 % ICU mortality to cancer admissions to PICU. This
figure lower than many series quote for previously healthy
585
children with community-acquired sepsis or acute respi-
ratory distress syndrome (ARDS) on PICU The observed
relative risk of PICU death with cancer is still highly
significant at 2.9 (95 % CI 2.7–3.1), but the truth is that
this reflects the overall improvement in PICU outcomes
more than cancer lagging behind. Acute myeloid leu-
kaemia cases had much worse outcome in multiple
variant analysis. Strikingly a 50 % survival of ECMO in
both solid and haematological cancer patients was seen—
though the post hematopoietic stem cell transplant group
did uniformly badly.
In summary, 2014 was characterized by two main
themes: mining of large datasets to reveal patterns in our
care of which we were previously unaware, and obser-
vations highlighting the many and varied gaps in our
knowledge.
Conflicts of interest None.
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